Cardio-Protection Against Cancer Treatment-Related Cardiac Dysfunction: Who is at Risk?

Abstract

Long-term survival of cancer patients has improved, and the sequelae of treatment have become more evident. Mortality rates of cancer patients, adjusted for age, have decreased globally, with a reduction by 17% from 1990 to 2019. The prevention of left ventricular dysfunction secondary to cancer treatment is still a medical challenge. Drug-induced cardiotoxicity is the main limiting factor for the administration of higher doses of anthracyclines. Addressing the anthracycline-induced cardiotoxicity is particularly important for pediatric cancer survivors, as it remains [...]